drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
Autologous T cells genetically modified to express a chimeric antigen receptor that binds mesothelin on tumor cells, triggering T-cell activation, cytokine release, and cytotoxic killing; evaluated via IV or local delivery, with lymphodepleting chemotherapy used to enhance expansion and optional combination with immune checkpoint inhibitors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous, Local injection
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor that recognizes mesothelin on tumor cells. CAR engagement triggers T-cell activation, cytokine release, proliferation, and targeted cytotoxic killing of mesothelin-expressing cancer cells; lymphodepleting chemotherapy may be used to enhance expansion.
drug_name
Anti-mesothelin (MSLN) CAR-T cells (UCLM802)
nct_id_drug_ref
NCT05783089